Ihr Broker

  • DAX 0,70
  • EUR/USD 0,50
  • GOLD 0,30

Nur Spreads

Keine Kommission

Jetzt registrieren

CFDs sind komplexe Instrumente und umfassen aufgrund der Hebelfinanzierung ein hohes Risiko, schnell Geld zu verlieren.

CALYPSO BIOTECH SA, corporate

CALYPSO BIOTECH SA,

16.11.2020 - 10:03:08

CALYPSO BIOTECH SA: Calypso Biotech announces successful dosing of first Phase 1 cohort with anti-Interleukin-15 monoclonal antibody CALY-002 for the treatment of Autoimmune Diseases

or contact info@calypsobiotech.com

ContactCalypso Biotech BVinfo@calypsobiotech.com

16.11.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

1148281??16.11.2020?

@ dgap.de